AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer

被引：6
|
作者：
Spirina, L. V. [1 ,2 ]
Avgustinovich, A. V. [1 ]
Afanas'ev, S. G. [1 ]
Kondakova, I. V. [1 ]
Volkov, M. Yu. [1 ]
Dobrodeev, A. Yu. [1 ]
Boronkina, A. I. [2 ]
机构：
[1] Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia
[2] Siberian State Med Univ, Minist Hlth Russian Federat, Tomsk, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2020年 / 170卷 / 01期
关键词：
gastric cancer; AKT; mTOR signaling cascade; PD; PD-L1; PD-L2; PATHWAY; AKT;
D O I：
10.1007/s10517-020-05007-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The peculiarities of gastric cancer development associated with the expression levels of components of the AKT/mTOR signaling cascade and PD, PD-L1, PD-L2 have not yet been identified. We revealed the fundamental changes in the expression AKT/mTOR and PD receptors and their ligands associated with dissemination of gastric cancer. An increase in the mRNA level of all components of this cascade was demonstrated. The expression of mTOR and AKT decreased against the background of enhanced expression of PTEN phosphatase. The increase in the expression of PD-1 receptors and PD-L1 and PD-L2 ligands was most pronounced in patients with distant metastases.
引用
收藏
页码：75 / 78
页数：4
相关论文
共 50 条
  • [21] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [22] PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
    Carter, Laura L.
    Leach, Michael W.
    Azoitei, Mihai L.
    Cui, Junqing
    Pelker, Jeffrey W.
    Jussif, Jason
    Benoit, Steve
    Ireland, Gretchen
    Luxenberg, Deborah
    Askew, G. Roger
    Milarski, Kim L.
    Groves, Christopher
    Brown, Tom
    Carito, Brenda A.
    Percival, Karen
    Carreno, Beatriz M.
    Collins, Mary
    Marusic, Suzana
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 182 (1-2) : 124 - 134
  • [23] PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
    Stevenson, Valentina B.
    Perry, Samantha N.
    Todd, Michelle
    Huckle, William R.
    LeRoith, Tanya
    VETERINARY PATHOLOGY, 2021, 58 (04) : 692 - 698
  • [24] EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINIC RELATIONSHIP
    Geng, S.
    Weng, J.
    Deng, C.
    Li, M.
    Lu, Z.
    Wu, P.
    Huang, X.
    Lai, P.
    Du, X.
    LEUKEMIA RESEARCH, 2017, 55 : S112 - S112
  • [25] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
    Yusof, Mohd Nazzary Mamat
    Chew, Kah Teik
    Kampan, Nirmala Chandralega
    Hafizz, Abdul Muzhill Hannaan Abdul
    Shafiee, Mohamad Nasir
    PLOS ONE, 2025, 20 (03):
  • [27] The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
    Pai, Sara I.
    Zandberg, Dan P.
    Strome, Scott E.
    ORAL ONCOLOGY, 2016, 61 : 152 - 158
  • [28] PD-L2 generates a signal through the PD-1 co-receptor distinct from that of PD-L1
    Srinivasamani, Anupallavi
    Liu, Qinying
    Curran, Michael
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [29] Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
    Xue, Chunyan
    Zhu, Dawei
    Chen, Lujun
    Xu, Yun
    Xu, Bin
    Zhang, Dachuan
    Jiang, Jingting
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (01) : 111 - 119
  • [30] PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation
    del Rio, Maria-Luisa
    Buhler, Leo
    Gibbons, Carrie
    Tian, Jiong
    Rodriguez-Barbosa, Jose-Ignacio
    TRANSPLANT INTERNATIONAL, 2008, 21 (11) : 1015 - 1028
12345